The FDA approved the VEGF inhibitor bevacizumab-awwb for the treatment of five types of cancer: nonsquamous non-small cell lung cancer, metastatic colorectal cancer, cervical cancer, renal cell carcinoma, and glioblastoma. A biosimilar to bevacizumab, the agent is the first such drug approved for the treatment of cancer.

中文翻译：

---

FDA批准了首个用于治疗癌症的生物仿制药

FDA批准了VEGF抑制剂贝伐单抗-awwb用于治疗五种类型的癌症：非鳞状非小细胞肺癌，转移性结直肠癌，宫颈癌，肾细胞癌和胶质母细胞瘤。该药是与贝伐单抗类似的生物仿制药，是第一种获准用于癌症治疗的药物。